N/A
Manufactured by 3D Imaging Drug Design and Development LLC
259 FDA adverse event reports analyzed
Last updated: 2026-04-15
AMMONIA N 13 is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by 3D Imaging Drug Design and Development LLC. The most commonly reported adverse reactions for AMMONIA N 13 include DRUG ABUSE, COUGH, DEPRESSION, CHEST PAIN, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AMMONIA N 13.
Out of 56 classified reports for AMMONIA N 13:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 259 FDA FAERS reports that mention AMMONIA N 13. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG ABUSE, COUGH, DEPRESSION, CHEST PAIN, DRUG INEFFECTIVE, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list 3D Imaging Drug Design and Development LLC in connection with AMMONIA N 13. Always verify the specific product and NDC with your pharmacist.